鼻咽癌肝转移患者肝部分切除术与经导管动脉化疗栓塞术的远期疗效比较分析

doi:10.19401/j.cnki.1007-3639.2025.05.009

摘要/Abstract

Key words: Hepatectomy, Liver metastasis, Nasopharyngeal carcinoma, Transcatheter arterial chemoembolization, Efficacy

中图分类号:

R735.7

王益林, 王鲁. 鼻咽癌肝转移患者肝部分切除术与经导管动脉化疗栓塞术的远期疗效比较分析[J]. 中国癌症杂志, 2025, 35(5): 505-509.

WANG Yilin, WANG Lu. A comparative analysis of the long-term efficacy between partial hepatectomy and transcatheter arterial chemoembolization in patients with liver metastasis from nasopharyngeal carcinoma[J]. China Oncology, 2025, 35(5): 505-509.

图/表 4

图1

表1

表2

图2

参考文献 28

[1]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2]	WEI W I, SHAM J S. Nasopharyngeal carcinoma[J]. Lancet, 2005, 365(9476): 2041-2054. doi: 10.1016/S0140-6736(05)66698-6 pmid: 15950718
[3]	JIN Y, CAI X Y, CAI Y C, et al. To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area[J]. Eur J Cancer, 2012, 48(6): 882-888. doi: 10.1016/j.ejca.2011.09.004 pmid: 22030451
[4]	LIU G Y, YE Y F, JIANG Y F, et al. Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial[J]. BMJ, 2024, 385: e077890.
[5]	LI W Z, HUA X, LV S H, et al. A scoring system based on nutritional and inflammatory parameters to predict the efficacy of first-line chemotherapy and survival outcomes for de novo metastatic nasopharyngeal carcinoma[J]. J Inflamm Res, 2021, 14: 817-828.
[6]	HUANG J, LI Q J, ZHENG Y, et al. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature[J]. BMC Cancer, 2014, 14: 818. doi: 10.1186/1471-2407-14-818 pmid: 25376591
[7]	FENG Y, ZHAO Y M, LI W W, et al. Hepatic resection prolongs overall survival in the selected patients with nasopharyngeal carcinoma liver metastases[J]. Eur J Surg Oncol, 2022, 48(10): 2202-2211. doi: 10.1016/j.ejso.2022.05.033 pmid: 35691781
[8]	ELIAS D, CAVALCANTI DE ALBUQUERQUE A, EGGENSPIELER P, et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients[J]. J Am Coll Surg, 1998, 187(5): 487-493.
[9]	WEITZ J, BLUMGART L H, FONG Y, et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma[J]. Ann Surg, 2005, 241(2): 269-276. doi: 10.1097/01.sla.0000150244.72285.ad pmid: 15650637
[10]	POL B, CAMPAN P, HARDWIGSEN J, et al. Morbidity of major hepatic resections: a 100-case prospective study[J]. Eur J Surg, 1999, 165(5): 446-453. doi: 10.1080/110241599750006686 pmid: 10391161
[11]	COUINAUD C. Anatomic principles of left and right regulated hepatectomy: technics[J]. J Chir (Paris), 1954, 70(12): 933-966. pmid: 13233306
[12]	KAWASAKI S, SUGIYAMA Y, IGA T, et al. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients[J]. Am J Gastroenterol, 1985, 80(10): 801-806. pmid: 4036939
[13]	CHUA D T T, SHAM J S T, AU G K H. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy[J]. Oral Oncol, 2003, 39(4): 361-366. doi: 10.1016/s1368-8375(02)00120-3 pmid: 12676255
[14]	LILLO S, MIRANDOLA A, VAI A, et al. Current status and future directions of proton therapy for head and neck carcinoma[J]. Cancers (Basel), 2024, 16(11): 2085.
[15]	YU Y F, LU G Z, WANG R J, et al. Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma[J]. Front Immunol, 2024, 15: 1415246.
[16]	LIU Q X, WANG J F, SUN C P, et al. The diagnosis and management of rare cystic liver metastases from nasopharyngeal carcinoma: a case report[J]. Medicine (Baltimore), 2018, 97(26): e11257.
[17]	JUAREZ-VIGNON WHALEY J J, AFKHAMI M, ONYSHCHENKO M, et al. Recurrent/metastatic nasopharyngeal carcinoma treatment from present to future: where are we and where are we heading?[J]. Curr Treat Options Oncol, 2023, 24(9): 1138-1166.
[18]	DAI J X, ZHANG B, SU Y X, et al. Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial[J]. JAMA Oncol, 2024, 10(4): 456-463.
[19]	DI CARLO S, CAVALLARO G, ROVERE F L, et al. Synchronous liver and peritoneal metastases from colorectal cancer: is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection a feasible option?[J]. Front Surg, 2022, 9: 1006591.
[20]	POON R T, FAN S T, LO C M, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1 222 consecutive patients from a prospective database[J]. Ann Surg, 2004, 240(4): 698-708;discussion 708-710.
[21]	CHAMBERLAIN R S, CANES D, BROWN K T, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?[J]. J Am Coll Surg, 2000, 190(4): 432-445.
[22]	FONG Y, COHEN A M, FORTNER J G, et al. Liver resection for colorectal metastases[J]. J Clin Oncol, 1997, 15(3): 938-946. doi: 10.1200/JCO.1997.15.3.938 pmid: 9060531
[23]	DELIS S, BILIATIS I, BOURLI A, et al. Surgical resection of a solitary liver metastasis from nasopharyngeal carcinoma: a case report[J]. Hepatobiliary Pancreat Dis Int, 2006, 5(4): 610-612.
[24]	CHEN L, WU L X, ZHANG L J, et al. Effect of metformin on hepatocellular carcinoma patients with type Ⅱ diabetes receiving transarterial chemoembolization: a multicenter retrospective cohort study[J]. Int J Surg, 2025, 111(1): 828-838.
[25]	TAN E H, KHOO K S, WEE J, et al. Phase Ⅱ trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma[J]. Ann Oncol, 1999, 10(2): 235-237.
[26]	FOO K F, TAN E H, LEONG S S, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type[J]. Ann Oncol, 2002, 13(1): 150-156. doi: 10.1093/annonc/mdf002 pmid: 11865813
[27]	FANDI A, BACHOUCHI M, AZLI N, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type[J]. J Clin Oncol, 2000, 18(6): 1324-1330. doi: 10.1200/JCO.2000.18.6.1324 pmid: 10715304
[28]	TREHUB Y, MALOVANNA A, ZEMSKOV S. The current state of perioperative chemotherapy in resectable colorectal liver metastases: a narrative review[J]. J Surg Oncol, 2025.

Characteristic	Resection group (n=20)	TACE group (n=20)	P value
Age/year median (range)	52 (39-70)	50 (38-70)	0.905
Gender			0.607
Male	17 (85)	16 (80)
Female	3 (15)	4 (20)
Liver metastasis presentation			0.999
Synchronous	1 (5)	1 (5)
Metachronous	19 (95)	19 (95)
Abdominal symptoms			0.999
Positive	8 (40)	8 (40)
Negative	12 (60)	12 (60)
Interval from NPC to hepatic metastasis/month			0.809
<12	5 (25)	4 (20)
≥12	15 (75)	16 (80)
Epstein-Barr virus			0.607
Positive	16 (80)	17 (85)
Negative	4 (20)	3 (15)
HBsAg			0.809
Positive	4 (20)	5 (25)
Negative	16 (80)	15 (75)

Item	Resection group (n=20)	TACE group (n=20)	P value
Lesion number			0.998
<3	16 (80)	16 (80)
≥3	4 (20)	4 (20)
Size of largest metastasis/cm			0.908
<5	12 (60)	13 (65)
≥5	8 (40)	7 (35)
Pathological type			0.999
Undifferentiated	20 (100)	20 (100)
Other types	0 (0)	0 (0)
Dose of radiotherapy/Gy median (range)			0.437
Nasopharyngeal	69 (66-74)	70 (66-76)
Regional lymph node	65 (51-69)	66 (52-71)
Adjuvant chemotherapy cycles of NPC			0.809
<3	16 (80)	15 (75)
≥3	4 (20)	5 (25)
Preoperative /pre-TACE complications
Yes	4 (20)	4 (20)	0.999
No	16 (80)	16 (80)
Postoperative/post-TACE complication			0.607
Yes	3 (15)	4 (20)
No	17 (85)	16 (80)
In-hospital mortality rate	0	0	0.999

鼻咽癌肝转移患者肝部分切除术与经导管动脉化疗栓塞术的远期疗效比较分析

A comparative analysis of the long-term efficacy between partial hepatectomy and transcatheter arterial chemoembolization in patients with liver metastasis from nasopharyngeal carcinoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	童刚, 华杨, 彭薇, 赵桔, 胡钧文. TACE联合安罗替尼及信迪利单抗治疗CNLC Ⅱb~Ⅲb期肝癌患者的疗效及安全性评估[J]. 中国癌症杂志, 2025, 35(5): 478-484.
[2]	王任飞, 卢改霞. 核医学分子影像在放射性碘难治性分化型甲状腺癌评估中的独特价值与争议[J]. 中国癌症杂志, 2025, 35(1): 49-57.
[3]	刘帅, 张凯, 张晓青, 栾巍. 派安普利单抗联合安罗替尼和化疗围手术期治疗局部进展期胃癌的探索性研究[J]. 中国癌症杂志, 2024, 34(7): 659-668.
[4]	熊茄妍, 雷伟, 游波, 张振新, 谢海静, 单颖, 夏天, 周勇. DDX6通过调控CKMT1A mRNA稳定性促进鼻咽癌细胞增殖和迁移的机制研究[J]. 中国癌症杂志, 2024, 34(5): 451-459.
[5]	罗扬, 孙涛, 邵志敏, 崔久嵬, 潘跃银, 张清媛, 程颖, 李惠平, 杨燕, 叶长生, 于国华, 王京芬, 刘运江, 刘新兰, 周宇红, 柏玉举, 谷元廷, 王晓稼, 徐兵河, 宋礼华. AK-HER2与参照药治疗HER2阳性转移性乳腺癌患者的疗效、体内代谢特征、安全性和免疫原性比较：一项多中心、随机、双盲Ⅲ期等效性临床试验[J]. 中国癌症杂志, 2024, 34(2): 161-175.
[6]	金奕滋, 林明曦, 张剑. 乳腺癌原发灶与肝转移灶受体表达差异研究[J]. 中国癌症杂志, 2023, 33(9): 834-843.
[7]	邹婷, 刘晓文. 胃癌同时性肝转移肝切除的疗效及预后分析[J]. 中国癌症杂志, 2023, 33(6): 605-612.
[8]	章平川, 杜鸣宇, 姚成云, 何侠, 尹丽. 环状RNA hsa_circ_0012779在鼻咽癌中的表达及其对细胞生物学行为影响的机制研究[J]. 中国癌症杂志, 2023, 33(5): 445-451.
[9]	左学良, 陈志强, 董润雨, 王智雄, 蔡娟. 联合检测LDHA和PD-L1在晚期胃癌PD-1抑制剂疗效预测及预后评估中的价值[J]. 中国癌症杂志, 2023, 33(5): 460-468.
[10]	唐天赐, 翟周诗佳, 李省苇, 王孝深, 倪晓晨. 广义等效均匀剂量优化方法在鼻咽癌调强放射治疗计划中的应用研究[J]. 中国癌症杂志, 2023, 33(3): 274-281.
[11]	江健韵, 翟瑞萍, 应红梅. 身体剂量参数对局部晚期鼻咽癌患者免疫细胞减少的影响分析：一项回顾性队列研究[J]. 中国癌症杂志, 2023, 33(10): 898-907.
[12]	陈瑛瑶, 储香玲, 俞昕, 苏春霞. 免疫检查点抑制剂疗效相关预测模型的研究进展[J]. 中国癌症杂志, 2023, 33(1): 61-70.
[13]	禹航, 刘文生, 张宁, 刘海宽, 陈洛海, 姚望, 范文哲, 李家平, 陈洁, 王于. 肝动脉栓塞术治疗囊性神经内分泌肿瘤肝转移的疗效及安全性分析[J]. 中国癌症杂志, 2022, 32(9): 794-799.
[14]	郭文婷, 慕转转, 李征, 张迎强, 靳晓娜, 林岩松. 可疑甲状腺球蛋白增高性分化型甲状腺癌患者经¹³¹I治疗后的临床转归[J]. 中国癌症杂志, 2022, 32(5): 410-416.
[15]	马光, 区晓敏, 胡超苏, 宋少莉, 杨忠毅. 治疗前¹⁸F-FLT和¹⁸F-FDG PET/CT摄取异质性在局部晚期鼻咽癌疗效预测中的价值[J]. 中国癌症杂志, 2022, 32(4): 309-315.